Scpharmaceuticals Inc (NASDAQ:SCPH) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus target price of $12.67 for the company and are forecasting that the company will post ($0.58) earnings per share for the current quarter, according to Zacks. Zacks has also given Scpharmaceuticals an industry rank of 101 out of 255 based on the ratings given to its competitors.
SCPH has been the subject of a number of research reports. ValuEngine raised Scpharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research downgraded Scpharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, May 11th. Jefferies Financial Group lowered their price target on Scpharmaceuticals from $26.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, June 14th. BMO Capital Markets lowered their price target on Scpharmaceuticals from $24.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, June 14th. Finally, Leerink Swann lowered their price target on Scpharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research report on Thursday, June 14th.
SCPH stock traded up $0.01 during trading on Friday, reaching $4.59. 52,710 shares of the stock traded hands, compared to its average volume of 48,005. Scpharmaceuticals has a 52-week low of $4.32 and a 52-week high of $18.17. The company has a current ratio of 19.23, a quick ratio of 19.23 and a debt-to-equity ratio of 0.10. The company has a market cap of $84.92 million and a PE ratio of -0.57.
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.